Literature DB >> 22753041

Review and update of SPRED1 mutations causing Legius syndrome.

Hilde Brems1, Eric Pasmant, Rick Van Minkelen, Katharina Wimmer, Meena Upadhyaya, Eric Legius, Ludwine Messiaen.   

Abstract

Legius syndrome presents as a mild neurofibromatosis type 1 (NF1) phenotype. Multiple café-au-lait spots and macrocephaly are present with or without axillary or inguinal freckling. Other typical NF1-associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas, and malignant peripheral nerve sheath tumors) are systematically absent. Legius syndrome is caused by germline loss-of-function SPRED1 mutations, resulting in overactivation of the RAS-MAPK signal transduction cascade. The first families were identified in 2007. Here, we review all identified SPRED1 mutations and summarize molecular, clinical, and functional data. All mutations have been deposited in a database created using the Leiden Open Variation Database software and accessible at http://www.lovd.nl/SPRED1. At present, the database contains 89 different mutations identified in 146 unrelated probands, including 16 new variants described for the first time. The database contains a spectrum of mutations: 29 missense, 28 frameshift, 19 nonsense, eight copy number changes, two splicing, one silent, one in-frame deletion and a mutation affecting the initiation codon. Sixty-three mutations and deletions are definitely pathogenic or most likely pathogenic, eight SPRED1 mutations are probably benign rare variants, and 17 SPRED1 missense mutations are still unclassified and need further family and functional studies to help with the interpretation.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753041     DOI: 10.1002/humu.22152

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  32 in total

1.  Differential allelic expression of SOS1 and hyperexpression of the activating SOS1 c.755C variant in a Noonan syndrome family.

Authors:  Silvia Moncini; Maria Teresa Bonati; Ilaria Morella; Luca Ferrari; Riccardo Brambilla; Paola Riva
Journal:  Eur J Hum Genet       Date:  2015-02-25       Impact factor: 4.246

Review 2.  RASopathy Gene Mutations in Melanoma.

Authors:  Ruth Halaban; Michael Krauthammer
Journal:  J Invest Dermatol       Date:  2016-05-25       Impact factor: 8.551

3.  SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype.

Authors:  Marialetizia Motta; Giulia Fasano; Sina Gredy; Julia Brinkmann; Adeline Alice Bonnard; Pelin Ozlem Simsek-Kiper; Elif Yilmaz Gulec; Leila Essaddam; Gulen Eda Utine; Ingrid Guarnetti Prandi; Martina Venditti; Francesca Pantaleoni; Francesca Clementina Radio; Andrea Ciolfi; Stefania Petrini; Federica Consoli; Cédric Vignal; Denis Hepbasli; Melanie Ullrich; Elke de Boer; Lisenka E L M Vissers; Sami Gritli; Cesare Rossi; Alessandro De Luca; Saayda Ben Becher; Bruce D Gelb; Bruno Dallapiccola; Antonella Lauri; Giovanni Chillemi; Kai Schuh; Hélène Cavé; Martin Zenker; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2021-10-08       Impact factor: 11.025

Review 4.  Ophthalmological assessment of children with neurofibromatosis type 1.

Authors:  Catherine Cassiman; Eric Legius; Werner Spileers; Ingele Casteels
Journal:  Eur J Pediatr       Date:  2013-05-25       Impact factor: 3.183

Review 5.  Feedback regulation of RTK signaling in development.

Authors:  Cynthia L Neben; Megan Lo; Natalia Jura; Ophir D Klein
Journal:  Dev Biol       Date:  2017-10-26       Impact factor: 3.582

6.  Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.

Authors:  Yasuko Hirata; Hilde Brems; Mayu Suzuki; Mitsuhiro Kanamori; Masahiro Okada; Rimpei Morita; Isabel Llano-Rivas; Toyoyuki Ose; Ludwine Messiaen; Eric Legius; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2015-12-03       Impact factor: 5.157

Review 7.  Recent advances in RASopathies.

Authors:  Yoko Aoki; Tetsuya Niihori; Shin-ichi Inoue; Yoichi Matsubara
Journal:  J Hum Genet       Date:  2015-10-08       Impact factor: 3.172

8.  Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?

Authors:  Eric Pasmant; Béatrice Parfait; Armelle Luscan; Philippe Goussard; Audrey Briand-Suleau; Ingrid Laurendeau; Corinne Fouveaut; Chrystel Leroy; Annelore Montadert; Pierre Wolkenstein; Michel Vidaud; Dominique Vidaud
Journal:  Eur J Hum Genet       Date:  2014-07-30       Impact factor: 4.246

9.  The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.

Authors:  Theresia Dunzendorfer-Matt; Ellen L Mercado; Karl Maly; Frank McCormick; Klaus Scheffzek
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-16       Impact factor: 11.205

Review 10.  A review of craniofacial and dental findings of the RASopathies.

Authors:  H Cao; N Alrejaye; O D Klein; A F Goodwin; S Oberoi
Journal:  Orthod Craniofac Res       Date:  2017-06       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.